Latest Earnings Results: Q2 '26
Estimated EPS
-$0.01
Reported EPS
-$0.07
Surprise
-600%
Estimated Rev
$13.59M
Reported Rev
$12.57M
Surprise
-7.51%
• Reported GAAP EPS of -$0.07 down -16.67% YoY • Reported revenue of $12.57M down -7.41% YoY
Bullish Takeaway
IRIDEX Corporation demonstrated growth in its core glaucoma product segment and maintained disciplined control over operating expenses, contributing to a reduction in total operating expenses compared to the prior year.
Bearish Takeaway
IRIDEX Corporation faced a revenue decline and margin compression during the quarter, while ongoing board-level governance tensions present structural risks that could distract from management and impact future strategic execution.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.04 | -- | -- | N/A |
Q2 '26 | -$0.01 | -$0.07 | -600.00% | MISSED |
Q1 '26 | -$0.07 | -$0.03 | 57.14% | BEAT |
Q4 '25 | -$0.02 | -$0.01 | 50.00% | BEAT |
Q3 '25 | -- | -$0.09 | -- | N/A |